Treatment strategies for dystonia

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 1, 2010, Pages 5-15

  Cloud, Leslie J ^a   Jinnah, H A ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Anticholinergics; Baclofen; Benzodiazepines; Dopaminergics; Dystonia; Tetrabenazine; Therapeutics

Indexed keywords

ALCOHOL; APOMORPHINE; ATROPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BACLOFEN; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BROMOCRIPTINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; LEVODOPA; LISURIDE; LITHIUM; NEUROLEPTIC AGENT; ORPHENADRINE; PROCYCLIDINE; PYRIDOSTIGMINE; QUETIAPINE; RISPERIDONE; SCOPOLAMINE; TETRABENAZINE; TRIHEXYPHENIDYL; VALPROIC ACID;

AGRANULOCYTOSIS; AKATHISIA; AMNESIA; ANTICHOLINERGIC SYNDROME; ANXIETY; BLEPHAROSPASM; BLURRED VISION; BODY POSTURE; BRAIN DEPTH STIMULATION; BRAIN SURGERY; CARDIOMYOPATHY; CERVICAL DYSTONIA; CHOREA; CLINICAL TRIAL; CONFUSION; CONSTIPATION; COORDINATION; DEPRESSION; DIABETES MELLITUS; DIPLOPIA; DISEASE CLASSIFICATION; DIZZINESS; DROWSINESS; DRUG ALCOHOL INTERACTION; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DYSPHAGIA; DYSPHONIA; DYSTONIA; ELECTROSURGERY; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; FUNCTIONAL DISEASE; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HUMAN; HYPERSALIVATION; HYPOTENSION; INDIVIDUALIZATION; INSOMNIA; INVOLUNTARY MOVEMENT; LIQUORRHEA; LOW DRUG DOSE; MUSCLE DENERVATION; MUSCLE WEAKNESS; MYOCARDITIS; MYOCLONUS; NAUSEA; NEUROSURGERY; NIGHTMARE; OCCUPATIONAL THERAPY; PALLIATIVE THERAPY; PALLIDOTOMY; PARKINSONISM; PATIENT SELECTION; PHYSIOTHERAPY; PRACTICE GUIDELINE; PSYCHOSIS; PTOSIS; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SPASTICITY; TARDIVE DYSKINESIA; THALAMOTOMY; TIC; TREATMENT PLANNING; TREMOR; URINARY HESITANCY; URINARY URGENCY; URINE RETENTION; WRITER'S CRAMP; XEROSTOMIA;

BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; DEEP BRAIN STIMULATION; DIAGNOSIS, DIFFERENTIAL; DOPAMINE ANTAGONISTS; DYSKINESIAS; DYSTONIA; DYSTONIC DISORDERS; HUMANS; INJECTIONS, INTRAMUSCULAR;

EID: 72849107056     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903426171     Document Type: Review

References (96)

1. Jankovic J. Treatment of dystonia. Lancet Neurol 2006;5:864-72
2. Goldman J, Comella C. Treatment Of dystonia. Clin Neuropharmacol 2003;26(2):102-108
3. BhidayasiriR, Tarsy D. Treatment of dystonia. Expert Rev Neurother 2006;6(6):863-886.
4. Ostrem JL, Starr PA. Treatment of dystonia with deep brain stimulation. Neurotherapeutics 2008;5(2):320-330
5. Marks WJJ. Brain surgery for dystonia. In: Stacey MA, editor, Handbook of dystonia. Informa Healtcare Usa, Inc.: New York; 2007. p. 393-406
6. Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986;36(2):160-164
7. Greene P, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 1988;3(1):46-60
8. Fahn S. High dosage anticholinergic therapy in dystonia. Neurology 1983;33(10):1255-1261
9. Tsao C. Low-dose trihexyphenidyl in the treatment of dystonia. Pediatr Neurol 1988;4:381
10. Taylor AE, Lang AE, Saint-Cyr JA, et al. Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies. Clin Neuropharmacol 1991;14(1):62-77
11. Burke RE, Fahn S. Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 1985;18:35-40
12. Greene P. Baclofen in the treatment of dystonia. Clin Neuropharmacol 1992;15:276-288
13. Greene PE, Fahn V. Baclofen in the treatment of idiopathic dystonia in children. Mov Disord 1992;7(1): 48-52
14. Sandyk R. Blepharospasm- successful treatment with baclofen and sodium valproate. A case report. S Afr Med J 1983;64:955-956
15. Sandyk R. Treatment of writer's cramp with sodium valproate and baclofen. A case report. S Afr Med J 1983;63:702-703
16. Brennan M, Ruff P, Sandyk R. Efficacy of a combination of sodium valproate and baclofen in meige's disease (idiopathic orofacial dystonia). BrMed J (Clin Res Ed). 1982 Sep 25;285(6345):853
17. Anca MH, Zaccai TF, Badarna S, et al. Natural history of oppenheim's dystonia (Dyt1) In Israel. J Child Neurol 2003;18:325-330
18. Jankovic J. Medical therapy and botulinum toxin in dystonia. Adv Neurol 1998;78:169-183
19. Hughes AJ, Lees AJ, Marsden CD. Paroxysmal dystonic head tremor. Mov Disord 1991;6(1):85-86
20. Jankovic J, Ford J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 1983;13(4):402-411
21. Davis TL, Charles PD, Burns RS. Clonazepam-sensitive intermittent dystonic tremor. South Med J 1995;88(10):1069-1071
22. Fletcher NA, Thompson PD, Scadding JW, et al. Successful treatment of childhood onset symptomatic dystonia with levodopa. J Neurol Neurosurg Psychiatry 1993;56(8):865-867
23. Barrett RE, Yahr MD, Duvoisin RC, et al. Torsion dystonia and spasmodic torticollis- results of treatment with L-dopa. Neurology 1970;20(11):107-113
24. Coleman M. Preliminary remarks on L-dopa therapy of dystonia. Neurology 1970;20(11):114-121
25. Mandell S. The treatment of dystonia with L-dopa and haloperidol. Neurology 1970;20(11):103-106
26. Greene P, Shale H, Fahn S. Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. Adv Neurol 1988;50:547-556
27. Lang AE. Dopamine agonists and antagonists in treatment of idiopathic dystonia. Adv Neurol 1988;50:561-570
28. Jinnah HA, Hess EJ. Experimental therapeutics for dystonia. Neurotherapeutics 2008;5:198-209
29. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1991;41:174-181
30. Ichinose H, Ohye T, Takahashi E, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutation in the Gtp-cyclohydrolase I gene. Nat Genet 1994;8:232-242
31. Nygaard T, Wilhelmsen K, Risch N, et al. Linkage mapping of dopa-responsive dystonia (Drd) to chromosome 14q. Nat Genet 1993;5:386-391
32. Steinberger D, Blau N, Goriuonov D, et al. Heterozygous mutation in 55-untranslated region of sepiapterin reductase gene (Spr) in a patient with dopa-responsive dystonia. Neurogenetics 2004;5:187-190
33. Steinberger D, Korinthenber R, Topka H, et al. Dopa-responsive dystonia: mutation analysis of Gch1 and analysis of therapeutic doses of L-dopa. Neurology 2000;55:1735-1737
34. Furukawa Y, Graf WD, Wong H, et al. Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (Th) gene mutations. Neurology 2001;56:260-353
35. Jimenez-Jimenez F, Garcia-Ruiz P, Molina J. Drug-induced movement disorders. Drug Saf 1997;16:180-204
36. Zuddas A, Cianchetti C. Efficacy of risperidone in idiopathic segmental dystonia. Lancet 1996;347:127-128
37. Reeves R, Liberto V. Treatment of essential blepharospasm with quetiapine. Mov Disord 2003;18(9):1072-1073
38. Karp BI, Goldstein SR, Chen R, et al. An open trial of clozapine for dystonia. Mov Disord 1999;14(4):652-657
39. Burbaud P, Guehl D, Lagueny A, et al. A pilot trial of clozapine in the treatment of cervical dystonia. J Neurol 1998;245(6-7):329-331
40. Wolf M, Mosnaim A. Improvement of axial dystonia with the administration of clozapine. Int J Clin Pharmacol Ther 1994;32:282-283
41. Thiel A, Dressler D, Kistel C, et al. Clozapine treatment of spasmodic torticollis. Neurology 1994;44:957-958
42. Kenney C, Hunter C, Jankovic J. Long-term tolerabilty of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2006;22(2):193-197
43. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982;11:41-47
44. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48(2):358-362
45. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38(3):391-394
46. Pekkenberg H, Fog R. Spontaneous oral dyskinesia. Results of treatment with tetrabenazine, pimozide, or both. Arch Neurol 1974;31:352-353
47. Reches A, Hassan M, Jackson V, et al. Lithium attenuates dopamine depleting effects of reserpine and tetrabenazine but not of alpha methyl-P-tyrosine. Life Sci 1983;33:157-160
48. Furukawa T, Ushizima I, Ono N. Modifications by litium of behavioral responses to methamphetamine and tetrabenazine. Psychopharmacologia 1975;42:243-248
49. Ohara S. Mexiletine in the treatment of spasmodic torticollis. Mov Disord 1998;13(6):934-940
50. Muller J. Riluzole therapy in cervical dystonia. Mov Disord 2002;17(1):198-200
51. Couper-Smartt J. Lithium in spasmodic torticollis. Lancet 1973;2:741-742
52. Koller WC, Biary N. Lithium ineffective in dystonia. Ann Neurol 1983;13:579-580
53. Isgreen WP. Carbamazepine in torsion dystonia. Adv Neurol 1976;14:411-416
54. Biary N, Koller W. Effect of alcohol on dystonia. Neurology 1985;35: 239-243
55. Lang AE, Riley DE. Tizanidine in cranial dystonia. Clin Neuropharmacol 1992;15:142-147
56. Fox SH. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 2002; 17:145-149
57. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol 2005;53(1):3-9 (Pubitemid 40522824)
58. Simpson DM. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology 2008;70:1699-1706
59. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987;37(4):616-623
60. Blitzer A. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 1989;98(2):93-97
61. Troung DD. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 1991;101(6 Pt 1):630-634
62. Hallett M, Benecke R, Blitzer A, Comella CL. Treatment of focal dystonias with botulinum toxin. Toxicon 2009;54(5):628-633
63. Pullman S. Approach to the treatment of limb disorders with botulinum toxin a: experience with 187 patients. Arch Neurol 1996;53:617-624
64. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-217
65. Jankovic J, Schwarz K. Ressponse and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746
66. Arce CA. Selective denervation in cervical dystonia. In: Stacey MA, editor, Handbook of dystonia. Informa Healthcare USA, Inc.: New York; 2007. p. 381-92
67. Bertrand CM. Selective peripheral denervation for spasmodic torticollis: surgical technique, results, and observations in 260 cases. Surg Neurol 1993;40:96-103
68. Chen X. Selective denervation and resection of cervical muscles in the treatment of spasmodic torticollis: long-term follow-up results in 207 cases. Stereotact Funct Neurosurg 2000;75(2-3):96-102
69. Braun V, Richter HP. Selective peripheral denervation for spasmodic torticollis: 13 year experience with 155 patients. J Neurosurg 2002;97: 207-212
70. Cohen-Gadol AA, Ahlskog JE, Matsumoto JY, et al. Selective peripheral deneration for the treatment of intractable spasmodic torticollis: experience with 168 patients at the mayo clinic. J Neurosurg 2003;98:1247-1254
71. Munchau A. Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. Brain 2001;124(Pt 4):769-783 (Pubitemid 32303835)
72. Narayan RK, Loubser PG, Jankovic J, et al. Intrathecal baclofen for intractable axial dystonia. Neurology 1991;41:1141-1142
73. Ford B. Use of intrathecal baclofen in the treatment of patients with dystonia. Arch Neurol 1996;53(12):1241-1246
74. Albright AL, Barry MJ, Shafron DH, et al. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001;43:652-657
75. Albright AL. Intrathecal baclofen for treatment of dystonia. In: Krauss JK, Jankovic J, Grossman R, editor, Surgery for parkinson's disease and movement disorders. Lippincott Williams &Williams: Philadelphia; 2001. pp. 316-322
76. Cooper IS. 20-year followup study of the neurosurgical treatment of dysotnia musculorum deformans. Adv Neurol 1976;14:423-452
77. Yianni J. Globus pallidus internus deep brain stimulation for dystonic conditions: a prospective audit. Mov Disord 2003;18(4):436-442 (Pubitemid 36527287)
78. Eltahawy HA. Primary dystonia is more responsive than secondary dystonia to pallidal interventions: outcome after pallidotomy or pallidal deep brain stimulation. Neurosurgery 2004;54:613-619
79. Vidailhet M, Vercueil L, Houeto JL. Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study. Lancet Neurol 2007;6:223-229
80. Vidailhet M. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005;352:459-467 (Pubitemid 40175972)
81. Kupsch A, Benecke R, Muller J. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006;355:1978-1990
82. Vesper J. Deep brain stimulation of the globus pallidus internus (Gpi) for torsion dystonia: a report of two cases. Acta Neurochir Suppl 2001;79:83-88
83. Tronnier V, Fogel W. Pallidal stimulation for generalized dystonia: report of 3 cases. J Neurosurg 2000;92:453-456
84. Vercueil L, Pollak P, Fraix V. Deep brain stimulation in the treatment of severe dystonia. J Neurol 2001;248:695-700 (Pubitemid 32695867)
85. Katayama M. Chronic stimulation of the globus pallidus internusfor control of primary generalized dystonia. Acta Neurochir Suppl 2003;87:125-128
86. Zorzi G, Marras C, Nardocci N. Stimulation of the globus pallidus internus for childhood-onset dystonia. Mov Disord 2005;20:1194-1200
87. Kumar R. Globus pallidus deep brain stimulation for generalized dystonia: clinical and pet investigation. Neurology 1999;53:871-874
88. Kiss ZH. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain 2007;130:2879-2886
89. Hung SW, Hamani C, Lozano AM. Long term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. Neurology 2007;68:457-459
90. Ostrem JL. Pallidal deep brain stimulation in patients with cranial-cervical dystonia (Meige syndrome). Mov Disord 2007;22(13):1885-1891
91. Houser M, Waltz T. Meige syndrome and pallidal deep brain stimulation. Mov Disord 2005;20(9):1203-1205
92. Foote KD, Sanchez JC, Okun MS. Staged deep brain stimulation for refractory craniofacial dystonia with blepharospasm: case report and physiology. Neurosurgery 2005;56(2):E415, discussion E415
93. Damier P, Thobois S, Witjas T. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry 2007;64:170-176
94. Candia V. Constraint-induced movement therapy for focal hand dystonia in musicians. Lancet 1999;353(9146):42
95. Priori A. Limb immobilization for the treatment of focal occupational dystonia. Neurology 2001;57(3):405-409
96. Jankovic J. Can peripheral trauma induce dystonia and other movement disorders? Yes! Mov Disord 2001;16(1):7-12